EuroPCR 2013: The Calm After The Technology Storm
This article was originally published in The Gray Sheet
Executive Summary
For the past several years, TAVI and renal denervation have dominated EuroPCR, the largest interventional cardiology conference in Europe. This year’s conference in Paris in May was more balanced, leaving room for interest in bioresorbable stents and mitral valves.
You may also be interested in...
At PCR, Drug-Eluting Stents From Asia, But At What Cost?
No one would place drug-eluting stents among the hot technologies showcased at this year’s EuroPCR, not with all of the buzz around renal denervation, percutaneous valves, and bioabsorbable stents and scaffolds. But an early morning session on DES from India and China underscored how the technology debate is changing in a world of cost constraints and emerging markets, particularly for mature categories.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.